Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Crizotinib delays intracranial TTP

Solomon – JCO 2016

ITT

tBM

No BM

Intracranial PD:

24%

38%

19%

Extracranial PD:

73%

57%

78%

(crizotinib data)

Treatment according to RECIST: switch vs. TBP

crizotinib showed non–statistically significant improvements in IC-TTP. icDCR w/crizo. was 85%